LANTHEUS HOLDINGS INC

Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma

20 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform

12 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027

06 Dec 2022 06:45:47 By Nasdaq GlobeNewswire

Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027

05 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial

29 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

28 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003

14 Nov 2022 06:00:03 By Nasdaq GlobeNewswire

Lantheus to Present at the Jefferies London Healthcare Conference

09 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Lantheus Reports Third Quarter 2022 Financial Results

03 Nov 2022 06:00:02 By Nasdaq GlobeNewswire

Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time

20 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data

17 Oct 2022 08:14:48 By Nasdaq GlobeNewswire

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

13 Sep 2022 07:06:00 By Nasdaq GlobeNewswire

Lantheus to Present at the Wells Fargo Healthcare Conference

01 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Lantheus Reports Second Quarter 2022 Financial Results

04 Aug 2022 06:00:03 By Nasdaq GlobeNewswire

Lantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8:00 a.m. Eastern Time

21 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer

15 Jun 2022 08:00:00 By Nasdaq GlobeNewswire

Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer

13 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Lantheus’ PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer

13 Jun 2022 06:45:00 By Nasdaq GlobeNewswire

Lantheus to Present at the Jefferies Healthcare Conference

02 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

26 May 2022 07:00:01 By Nasdaq GlobeNewswire